PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le *et al.*	
FILING DATE: December 7, 2001	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
MP	AA	4,603,106	07/29/86	Cerami *et al.*	435	7	
	AB	4,822,776	04/18/89	Cerami *et al.*	514	21	
	AC	5,658,570	08/19/97	Newman *et al.*	424	184.1	
	AD	5,750,105	5/12/98	Newman *et al.*	424	133.1	
	AE	5,231,024	7/27/93	Moeller *et al.*	435	240.27	
	AF	5,223,395	06/29/93	Gero	435	71	
	AG	5,436,154	07/25/95	Barbanti *et al.*	435	240.27	
	AH	5,654,407	08/05/97	Boyle *et al.*	530	388.15	
	AI	5,700,788	12/23/97	Mongelli *et al.*	514	91	
	AJ	5,730,975	03/24/98	Hotamisligil *et al.*	424	130.1	
	AK	5,741,488	04/21/98	Feldman *et al.*	424	154.1	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AL	0 212 489 A2	04 MAR 87	EPO				
	AM	0 218 868 A2	22 APR 87	EPO				
	AN	0 288 088 A2	26 OCT 88	EPO				
	AO	0 308 378 A2	22 MAR 89	EPO				
	AP	0 380 068 A1	01 AUG 90	EPO				
	AQ	0 393 438 A3	24 OCT 90	EPO				

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

	AR	Beutler, B. *et al.*, "Identity of tumour necrosis factor and the macrophage-secreted factor cachectin," *Nature*, *316*:552-554 (1985).
	AS	Beutler, B. *et al.*, "Passive Immunization Against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin," *Science*, *229*:869-871 (1985).
MP	AT	Morrison, Sherie L., "Transfectomas Provide Novel Chimeric Antibodies," *Science*, *229*:1202-1207 (1985).

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT	
Junming Le *et al.*	
FILING DATE	**GROUP**
December 7, 2001	1644

RECEIVED
SEP 25 2002
TECH CENTER 1600/29

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AA2	5,776,947	07/07/98	Kroemer *et al.*	514	312	
	AB2	6,015,558	01/18/00	Hotamisligil *et al.*	424	142.1	
	AC2	6,172,202 B1	01/09/01	Marcucci *et al.*	530	406	
	AD2	6,194,451 B1	02/27/01	Alpegiani *et al.*	514	459	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AL2	0 398 327 A1	22 NOV 90	EPO				
	AM2	0 412 486 A1	13 FEB 91	EPO				
	AN2	0 433 900 A1	26 JUN 91	EPO				
	AO2	0 526 905 A2	10 FEB 93	EPO				
	AP2	WO91/02078	21 FEB 91	PCT				
	AQ2	WO92/07076	30 APR 92	PCT				

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	AU	Liang, Chi-Ming *et al.*, "Production and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor/Cachectin," *Biochem. & Biophy. Res. Comm., 137(2)*:847-854 (1986).
	AV	Hirai, Makoto *et al.*, "Production and characterization of monoclonal antibodies to human tumor necrosis factor," *J. of Immun. Methods, 96*:57-62 (1987).
	AW	Piguet, Pierre-Francois *et al.*, "Tumor Necrosis Factor/Cachectin is an Effector of Skin and Gut Lesions of the Acute Phase of Graft-vs.-Host Disease," *J. Exp. Med., 166*:1280-1289 (1987).
	AX	Meager, Anthony *et al.*, "Preparation and Characterization of Monoclonal Antibodies Directed Against Antigenic Determinants of Recombinant Human Tumour Necrosis Factor (rTNF)," *Hybridoma, 6(3)*:305-311 (1987).
	AY	Fendly, Brian M. *et al.*, "Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor," *Hybridoma, 6(4)*:359-370 (1987).

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le *et al.*	
FILING DATE: December 7, 2001	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AL3	WO 92/13095	06 AUG 92	PCT				
	AM3	0 260 610 A2	23 MAR 88	EPO				
	AN3	91/09967	11 JUL 91	PCT				
	A03	0 351 789 A2	24 JAN 90	EPO				
	AP3	0 350 690 A2	17 JAN 90	EPO				
	AQ3	90/00902	08 FEB 90	PCT				
	AL4	WO 92/11383	09 JUL 92	PCT				
	AM4	WO 93/02108	04 FEB 93	PCT				
	AN4	WO 92/16553	19 MAR 92	PCT				

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

AZ	Bringman, Timothy S. and Aggarwal, Bharat B., "Monoclonal Antibodies to Human Tumor Necrosis Factors Alpha and Beta: Applications for Affinity Purification, Immunoassays, and as Structural Probes," *Hybridoma*, 6(5):489-507 (1987).
AR2	Tracey, Kevin J. *et al.*, "Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia," *Nature*, *330*:662-664 (1987).
AS2	Nagai, M. *et al.*, "Antibody to tumor necrosis factor (TNF) reduces endotoxin fever," *Experientia*, 44:606-607 (1988).
AT2	Shimamoto, Yoshinori *et al.*, "Monoclonal antibodies against human recombinant tumor necrosis factor: prevention of endotoxic shock," *Immunology Letters*, 17:311-318 (1988).
AU2	Di Giovine, Francesco, S. *et al.*, "Tumour necrosis factor in synovial exudates," *Annals of the Rheumatic Diseases*, 47:768-772 (1988).
AV2	Collins, M.S. *et al.*, "Immunoprophylaxis of Polymicrobic Cellulitis with a Human Monoclonal Antibody Against Lipopolysaccharide Antigen of Pseudomonas aeruginosa," Abstract E-63, *Abstracts of Annual Meeting 1989*.

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT	
Junming Le *et al.*	
FILING DATE	**GROUP**
December 7, 2001	1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AO4	WO 91/09967	11 JUL 91	PCT				
	AP4	0 486 526 B2	07 MAR 01	EPO				
	AQ4	WO 92/02190	10 JUN 92	PCT				
	AL5	0 288 088 B1	26 OCT 88	EPO				
	AM5	0 351 789 B1	24 JAN 90	EPO				
	AN5	0 453 898 A2	30 OCT 91	EPO				X
	AO5	0 585 705 A1	09 MAR 94	EPO				
	AP5	0 614 984 A2	14 SEP 94	EPO				
	AQ5	0 663 836 B1	26 JUL 95	EPO				
	AL6	WO 89/08460	21 SEP 89	PCT				
	AM6	WO 90/01950	08 MAR 90	PCT				

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

	AW2	Exley, A.R. *et al.*, "Monoclonal Antibody (Mab) to Recombinant Human Tumour Necrosis Factor (rhTNF) in the Prophylaxis and Treatment of Endotoxic Shock in Cynomolgus Monkeys," *Medical Research Society*, Abstract 184, p. 50 (1989).
	AX2	Cross, A.S. *et al.*, "Pretreatment with Recombinant Murine Tumor Necrosis Factor α/Cachectin and Murine Interleukin 1 α Protects Mice from Lethal Bacterial Infection," *J of Exp Med., 169*:2021-2027 (1989).
	AY2	Engelmann, Hartmut *et al.*, "A Tumor Necrosis Factor-binding Protein Purified to Homogeneity from Human Urine Protects Cells from Tumor Necrosis Factor Toxicity," *J. of Bio. Chem., 264(20)*:11974-11980 (1989).

EXAMINER	DATE CONSIDERED
THUMBER	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le *et al.*	
FILING DATE: December 7, 2001	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO
	AN6	WO 91/04054	04 APR 91	PCT				
	AO6	WO 92/01472	06 FEB 92	PCT				
	AP6	WO 93/11236	10 JUN 93	PCT				
	AQ6	WO 94/08609	28 APR 94	PCT				
	AL7	WO 94/08619	28 APR 94	PCT				

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

	AZ2	Kawasaki, Hajime *et al.*, "Analysis of Endotoxin Fever in Rabbits by Using a Monoclonal Antibody to Tumor Necrosis Factor (Cachectin)," *Infection and Immunity, 57(10)*:3131-3135 (1989).
	AR3	Fong, Yuman *et al.*, "Antibodies to Cachectin/Tumor Necrosis Factor Reduce Interleukin 1β and Interleukin 6 Appearance During Lethal Bacteremia," *J. Exp. Med., 170*:1627-1633 (1989).
	AS3	Von Asmuth, E.J.U. *et al.*, "Tumour Necrosis Factor Alpha (TNF-α) and Interleukin 6 in a Zymosan-Induced Shock Model," *Scand. J. Immunol., 32*:313-319 (1990).
	AT3	Herve, P. *et al.*, "Monoclonal Anti TNF α Antibody for the Treatment of Severe Acute GvHD in Humans," Abstract 3.25, *Lymphoma Res. 9*:591 (1990).
	AU3	Silva, Ayona T. *et al.*, "Prophylactic and Therapeutic Effects of a Monoclonal Antibody to Tumor Necrosis Factor-α in Experimental Gram-Negative Shock," *J. of Infectious Diseases, 162*:421-427 (1990).
	AV3	Opal, Steven M. *et al.*, "Efficacy of a Monoclonal Antibody Directed Against Tumor Necrosis Factor in Protecting Neutropenic Rats from Lethal Infection with *Pseudomonas aeruginosa*," *J. of Infectious Diseases, 161*:1148-1152 (1990).
	AW3	Tavernier, Jan *et al.*, "Analysis of the Structure-Function Relationship of Tumour Necrosis Factor. Human/Mouse Chimeric TNF Proteins: General Properties and Epitope Analysis," *J. Mol. Biol., 211*:493-501 (1990).
	AX3	Lucas, R. *et al.*, "Generation and characterization of a neutralizing rat anti-rm TNF-α monoclonal antibody," *Immunology, 71*:218-223 (1990).

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le et al.	
FILING DATE: December 7, 2001	GROUP: 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AY3	Hinshaw, L.B. *et al.*, "Survival of Primates in LD_{100} Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNFα)," *Circulatory Shock*, *30*:279-292 (1990).
	AZ3	Nophar, Yaron *et al.*, "Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor," *The EMBO Journal*, *9(10)*:3269-3278 (1990).
	AR4	Engelmann, Hartmut *et al.*, "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," *J. of Bio. Chem.*, *265(3)*:1531-1536 (1990).
	AS4	Verhoef, J. and Torensma, R., "Prospects for Monoclonal Antibodies in the Diagnosis and Treatment of Bacterial Infections," *Eur. J. Clin. Microbiol. Dis.*, *9(4)*:247-250 (1990).
	AT4	Loetscher, Hansruedi *et al.*, "Molecular Cloning and Expression of the Human 55 kd Tumor Necrosis Factor Receptor," *Cell*, *61*:351-359 (1990).
	AU4	Schall, Thomas J. *et al.*, "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," *Cell*, *61*:361-370 (1990).
	AV4	Akama, Hideto *et al.*, "Mononuclear Cells Enhance Prostaglandin E_2 Production of Polymorphonuclear Leukocytes via Tumor Necrosis Factor α," *Biochemical and Biophysical Research Comm.*, *168(2)*:857-862 (1990).
	AW4	Exley, A.R. *et al.*, "Monoclonal antibody to TNF in severe septic shock," *The Lancet*, *335*:1275-1277 (1990).
	AX4	Möller, Achim *et al.*, "Monoclonal Antibodies to Human Tumor Necrosis Factor α: In Vitro and In Vivo Application," *Cytokine*, *2(3)*:162-169 (1990).
	AY4	Ruddle, Nancy H. *et al.*, "An Antibody to Lymphotoxin and Tumor Necrosis Factor Prevents Transfer of Experimental Allergic Encephalomyelitis," *J. Exp. Med.*, *172*:1193-1200 (1990).

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le *et al.*	
FILING DATE: December 7, 2001	GROUP: 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NU	AZ4	Galloway, Cynthia J. *et al.*, "Monoclonal anti-tumor necrosis factor (TNF) antibodies protect mouse and human cells from TNF cytotoxicity," *J. of Immunological Methods, 140*:37-43 (1991).
	AR5	Waldmann, Thomas A., "Monoclonal Antibodies in Diagnosis and Therapy," *Science, 252*:1657-1662 (1991).
	AS5	Aderka, Dan *et al.*, "The Possible Role of Tumor Necrosis Factor (TNF) and Its Natural Inhibitors, The Soluble-TNF Receptors, In Autoimmune Diseases," *Israel J. Med. Sci., 28(2)*:126-130 (1992).
	AT5	Pennington, James, "TNF: Therapeutic Target in Patients with Sepsis," *ASM News, 58(9)*:479-482 (1992).
	AU5	Harris, William J. and Emery, Steven, "Therapeutic antibodies - the coming of age," *TBTECH, 11*:42-44 (1993).
	AV5	Parrillo, Joseph E., "Pathogenetic Mechanisms of Septic Shock," *N.E. Journal of Medicine, 328(20)*:1471-1477 (1993).
	AW5	Aggarwal, Bharat B. *et al.*, "Human Tumor Necrosis Factor Production, Purification and Characterization," *J. of Biol. Chem., 260(4)*:2345-2354 (1985).
	AX5	Beutler, B. *et al.*, "Purification of Cachectin, A Lipoprotein Lipase-Suppressing Hormone Secreted by Endotoxin-induced RAW 264.7 Cells," *J. Exp. Med., 161*:984-995 (1985).
	AY5	Echtenacher, Bernd *et al.*, "Requirement of Endogenous Tumor Necrosis Factor/Cachectin for Recovery from Experimental Peritonitis," *J. of Immunology, 145(11)*:3762-3766 (1990).
	AZ5	Smith, Craig R., "Human and Chimeric Antibodies to LPS and TNF," 4Abstract, *Endotoxemia & Sepsis Conference* (1991).
	AR6	Bodmer, Mark, "Humanized Antibodies for Anti-TNF Therapy," Abstract, *Endotoxemia & Sepsis Conference* (1991).
	AS6	Genebank Accession, No. N90300 (1989,November 1).
	AT6	Genebank Accession, No. M32046 (1990,June 15).
	AU6	Paulus, H., "Preparation and Biomedical Applications of Bispecific Antibodies", *Behring Inst. Mitt*, No.78:118-132 (1985).
	AV6	Whittle, Nigel, *et al.*, "Construction and Expression of a CDR-Grafted Anti-TNF Antibody," *J. Cell Biochem*, Supl. 13A:96 (1989).
	AW6	Gorman, S.D. and Clark, M.R., "Humanisation of monoclonal antibodies for therapy," *Sem Immunol*, 2:457-466 (1990).
NU	AX6	Starnes, H. Fletcher, Jr., *et al.*, "ANTI-IL-6 Monoclonal Antibodies Protect Against Lethal *Escherichia Coli* Infection and Lethal Tumor Necrosis Factor« Challenge in Mice," *J Immunol*, 145:4185-4191 (1990).

EXAMINER	DATE CONSIDERED
PHILIP GAMBEL	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT	
Junming Le *et al.*	
FILING DATE	GROUP
December 7, 2001	1644

RECEIVED
SEP 25 2002
TECH CENTER 1600/2900

OTPE
SEP 23 2002
PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

	AY6	Duncombe, Andrew *et al.*, "Tumor Necrosis Factor Mediates Autocrine Growth Inhibition in a Chronic Leukemia," *J Immunol*, 143:3828-3834 (1989).
	AZ6	Aderka, Dan *et al.*, "IL-6 Inhibits Lipopolysaccharide-Induced tumor Necrosis Factor Production in Cultured Human Monocytes, U937 Cells, and in Mice," *J Immunol*, 143:3517-3523 (1989).
	AR7	Aderka, Dan, "Role of Tumor Necrosis Factor in the Pathogenesis of Intravascular Coagulopathy of Sepsis: Potential New Therapeutic Implications," *Isr J Med Sci*, 27:52-60 (1991).
	AS7	Lassalle, Ph., *et al.*, "Potential Implicaton of Endothelial Cells in Bronchial Asthma," *Int Arch Allergy Appl Immunol*, 94:233-238 (1991).
	AT7	Fong, Yuman and Lowry, Stephen F., "Tumor Necrosis Factor in the Pathophysiology of Infection and Sepsis," *Clin Immunol Immunopathol*, 55:157-170 (1990).
	AU7	Eck, Michael J. and Sprang, Stephen R., "The Structure of Tumor Necrosis Factor-∝ at 2.6 Å Resolution," *J Biol Chem*, 264:17595-17605 (1989).
	AV7	Gillies, Stephen D. *et al.*, "High-level expression of chimeric antibodies using adapted cDNA variable region cassettes," *J Immunol Methods*, 125:191-202 (1989).
	AW7	Kameyama, Koh-zoh, *et al.*, "Convenient plasmid vectors for construction of chimeric mouse/human antibodies," *FEBS Lett*, 244:301-306 (1989).
	AX7	Hayashi, H. *et al.*, "An Enzyme-linked Immunosorbent Assay for Recombinant Human Tumor Necrosis Factor Using Monoclonal Antibody," *Recent Adv. Chemother*, 820-821 (1985).
	AY7	Hirai, Makoto *et al.*, "Production and characterization of monoclonal antibodies to human tumor necrosis factor," *J Immunol Methods*, 96:57-62 (1987).
	AZ7	Sunahara, N. et al., "Simple enzyme immunoassay methods for recombinant human tumor necrosis factor ∝ and its antibodies using a bacterial cell wall carrier," J Immunol Methods, 109:203-214 (1988).
	AR8	Oliff, A., *et al.*, "Tumors Secreting Human TNF/Cachectin Induce Cachexia in Mice," *Cell*, 50:555-563 (1987).
	AS8	Mule, J.J., *et al.*, "Antitumor Activity of Recombinant Interleukin 6 in Mice," *The Journal of Experimental Medicine*, 171:629-636 (1990).
	AT8	Luettig, B., *et al.*, "Evidence For The Existence Of Two Forms Of Membrane Tumor Necrosis Factor: An Integral Protein And A Molecule Attached To Its Receptor," *The Journal of Immunology*, 143:4034-4038 (1989).

EXAMINER	DATE CONSIDERED
Phillip Gambel	9/29/04

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 0975.1005-014	APPLICATION NO. 10/010,229
INFORMATION DISCLOSURE CITATION IN AN APPLICATION	APPLICANT Junming Le *et al.*	
September 19, 2002 (Use several sheets if necessary)	FILING DATE December 7, 2001	GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AU8	Barbuto, J.A.M., *et al* "Production of neutralizing antibodies to tumor necrosis factor by human tumor-infiltrating B lymphocytes," *Proceedings of the American Association for Cancer Research*, 34:487, Abstract 2904, (1993).
	AV8	Bendtzen, K., *et al.*, "Auto-Antibodies To IL-1α and TNFα In Normal Individuals And In Infectious And Immunoinflammatory Disorders," *The Physiological and Pathological Effects of Cytokines*, 10B:447-452 (1990).
	AW8	Fomsgaard, A., *et al.*, "Auto-Antibodies To Tumour Necrosis Factor α In Healthy Humans And Patients With Inflammatory Diseases And Gram-Negative Bacterial Infections," *Scand. J. Immunol.*, 30:219-223 (1989).
	AX8	James, K. and Bell, G.T., "Human Monoclonal Antibody Production Current Status And Future Prospects," *Journal of Immunological Methods*, 100:5-40 (1987).
	AY8	Alberts, B. *et al.*, Molecular Biology of the Cell, Garland Publishing Inc., pp 182-183 (1983).
	AZ8	Simpson, S.Q., *et al.*, "Role Of Tumor Necrosis Factor In Sepsis And Acute Lung Injury," *Critical Care Clinics*, 5:27-47 (1989).
	AR9	Bendtzen, K., *et al.*,"Native inhibitors (autoantibodies) of IL-1α and TNF," *Immunology Today*, 10(7):222 (1989).
	AS9	Davenport, C., *et al.*, "Stimulation Of Human B Cells Specific For Candida Albicans For Monoclonal Antibody Production," *FEMS Microbiol Immunol*, 4(6):335-343 Abstract (1992).
	AT9	Pennica, D., *et al.*, "Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin," *Nature*, 312(20/27):724-729 (1984).
	AU9	Gray, P.W., *et al.*, "Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity," *Nature*, 312(20/27):721-724 (1984).
	AV9	Petersen, C.M., *et al.*, "Bioactive human recombinant tumor necrosis factor-α: an unstable dimer?*," *Eur. J. Immunol.*, 19:1887-1894 (1989).
	AW9	Smith, C. A., *et al.*, "A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins," *Science*, 248:1019-1023 (1990).
	AX9	Brennan, F.M., *et al.*, "Inhibitory Effect Of TNFα Antibodies On Synovial Cell Interleukin-1 Production In Rheumatoid Arthritis," *The Lancet*, 244-247 (1989).
	AY9	Hahn, T., *et al.*, "Use of monoclonal antibodies to a human cytotoxin for its isolation and for examining the self-induction of resistance to this protein," *Proc. Natl. Acac. Sci. USA* 82:3814-3818 (1985).

EXAMINER	DATE CONSIDERED
PHILLIP GAMBEL	9/29/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

September 19, 2002

(Use several sheets if necessary)

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,228
APPLICANT	
Junming Le *et al.*	
FILING DATE	**GROUP**
December 7, 2001	1644

RECEIVED
SEP 25 2002
TECH CENTER 1600/2900

OIPE
SEP 23 2002
PATENT & TRADEMARK OFFICE

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

	AZ9	Grau, G.E., *et al.*, "Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral Malaria," *Science*, 237:1210-1212 (1987).
	AR10	Barbanti, E., *et al.*, "A high-affinity neutralizing anti-human TNF-alpha monoclonal antibody that cross-reacts with human TNF-beta," *Abstracts*, March 6th-9th (1991).
	AS10	Jones, E.Y., *et al.*, "Structure of tumour necrosis factor," *Nature*, 338:225-228 (1989).
	AT10	Clark, W. R., "Types of Antibody Reactions," In *The Experimental Foundations of Modern Immunology*, (NY: John Wiley & Sons, Inc.) 4th Ed., pp 143-155 (1991).
	AU10	Beutler, B., *et al.*, "Cachectin and tumour necrosis factor as two sides of the same biological coin," *Nature*, 320:584-588 (1986).
	AV10	Folks, T. M., *et al.*, "Tumor Necrosis factor α induces expression of human immunodeficiency virus in a chronically infected T-cell clone," *Proc. Natl. Acad. Sci. USA*, 86:2365-2358 (1989).
	AW10	Hird, V., *et al.*, "Immunotherapy with Monoclonal Antibodies," In *Genes and Cancer* (John Wiley & Sons, Ltd.)(1990). PAGES 183-189.
	AX10	*Rhein, R.*, "Another sepsis drug down-Immunex' TNF receptor," *Biotechnology Newswatch*, Monday, October 4, 1993, pp. 1,3.
	AY10	Boyle, P., *et al.*, "A Novel Monoclonal Human IgM Autoantibody which Binds Recombinant Human and Mouse Tumor Necrosis Factor-α," *Cellular Immunology*, 152:556-568 (1993).
	AZ10	Boyle, P., *et al.*, "The B5 Monoclonal Human Autoantibody Binds to Cell Surface TNFα on Human Lymphoid Cells and Cell Lines and Appears to Recognize a Novel Epitope," *Cellular Immunology*, 152:569-581 (1993).
	AR11	Sheehan, K.C.F., *et al.*, "Generation And Characterization Of Hamster Monoclonal Antibodies That Neutralize Murine Tumor Necrosis Factors," *The Journal of Immunology*, 142(11):3884-3893 (1989).
	AS11	Jacob, C.O., *et al.*, "Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis," *Nature*, 331:356-358 (1988).

EXAMINER	DATE CONSIDERED
PHILIP GAMBEL	9/24/04

PTO-1449 REPRODUCED

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

October 9, 2002

(Use several sheets if necessary)

OIPE SCANNED OCT 15 2002 PATENT & TRADEMARK OFFICE

ATTORNEY DOCKET NO.	APPLICATION NO.
0975.1005-014	10/010,229
APPLICANT: Junming Le *et al.*	
FILING DATE: December 7, 2001	GROUP: 1644

RECEIVED
OCT 18 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
	AE2	4,816,567	03/28/89	Cabilly et al.			
	AF2	5,075,236	12/24/91	Yone et al.			
	AG2	5,959,087	09/28/99	Rathjen et al.			
	AH2	5,360,716	11/01/94	Ohmoto, Y. et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION YES	TRANSLATION NO
	AM7	WO92/01059	23 JAN 92	PCT				
	AN7	02-227095	10 SEP 90	JP			X	
	AO7	61-047500	07 MAR 86	JP			X	

OTHER DOCUMENTS ***(Including Author, Title, Date, Pertinent Pages, Etc.)***

	AT11	Yan, L. et al., "Preparation and Characterization of Monoclonal Antibodies Against Recombinant Human Tumor Necrosis Factor Alpha", *Chinese J. Biotechnology*, 7(2):121-126 (1991).
	AU11	Mateo, C. et al., "Removal of Amphipathic Epitopes from Genetically Engineered Antibodies: Production of Modified Immunoglobulins with Reduced Immunogenicity", *Hybridoma*, 19(6):463-471 (2000).
	AV11	Paul, W.E. (Ed.), *Fundamental Immunology*, 3rd Edition, Pub. Raven Press Ltd., pp. 292-293 (1993).
	AW11	Borrebaeck, C.A.K. (Ed.), *Antibody Engineering*, 2nd Edition, Pub. Oxford University Press, p. 291 (1995).
	AX11	Socher, S. *et al.*, "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor", *Proc. Natl. Acad. Sci.*, USA 84:8829-8833 (1987).
	AY11	Goh,C., "Tumour Necrosis Factors in Clinical Practice", *Annals of the Academy of Medicine*, 19(2):235-239 (1990).

EXAMINER: Phillip Gambel

DATE CONSIDERED: 9/29/04

Statement Under 37 CFR 1.97(e)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[ ] Copies of the cited references are enclosed.

[X] Copies of cited references are enclosed except those entered in prior application, U.S. Application No. 09/927,703, to which priority under 35 U.S.C. 120 is claimed. The earlier application contains copies of the cited references.

[ ] The listed references were cited in the enclosed International Search Report in a counterpart foreign application.

[X] The "concise explanation" requirement (non-English references) for references AN7 and AO7 under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[X] the enclosed English language abstracts and also reference AH2, which is a U.S. equivalent of AN7. Copies of references AH2, AN7 and AO7 are enclosed in prior application U.S. Application No. 09/927,703, to which priority under 35 U.S.C. 120 is claimed.

[X] Applicant requests that the following pending applications be considered:

Examiner's Initials

U.S. Patent Application No. 10/227,488, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 23, 2002, Docket No.: 0975.1005-02S

Examiner

9/14/04
Date

Statement Under 37 CFR 1.97(e)

[ ] Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

[ ] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)
Applies to original applications (other than design) filed on or after May 29, 2000

[ ] Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

[X] Enclosed herewith is form PTO-1449:

[ ] Copies of the cited references are enclosed.

[X] Copies of cited references are enclosed except those entered in prior applications, U.S. Application No. 09/927,703, U.S. Application No.: 09/756,398 and U.S. Application No.: 09/133,119 to which priority under 35 U.S.C. 120 is claimed. The earlier applications contains copies of the cited references.

[X] Some of the listed references were cited in the enclosed International Search Report and European Search Report in a counterpart foreign application. [ISR References AS, AT, AU, AZ, AX7, AY7 and AZ7; ESR References AP2, AM3, AN3, AO3, AP3, AQ3 and AL5]

[ ] The "concise explanation" requirement (non-English references) for reference(s) [ ] under 37 CFR 1.98(a)(3) is satisfied by:

[ ] the explanation provided on the attached sheet.

[ ] the explanation provided in the Specification.

[ ] submission of the enclosed International Search Report.

[ ] the enclosed English language abstract.

[X] Applicant requests that the following pending applications be considered:

Examiner's Initials

U.S. Patent Application No. 09/756,398, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-006

U.S. Patent Application No. 09/756,301, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 8, 2001, Docket No.: 0975.1005-008

PHILIP GAMBA 08/12/04

U.S. Patent Application No. 09/766,535, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 18, 2001, Docket No.: 0975.1005-010

U.S. Patent Application No. 09/897,724, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 2, 2001, Docket No.: 0975.1005-012

U.S. Patent Application No. 09/927,703, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed August 10, 2001, Docket No.: 0975.1005-013

U.S. Patent Application No. 10/043,450, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-015

U.S. Patent Application No. 10/044,534, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-016

U.S. Patent Application No. 10/043,432, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-017

U.S. Patent Application No. 10/043,436, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed January 10, 2002, Docket No.: 0975.1005-018

U.S. Patent Application No.10/176,460, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 20, 2002, Docket No.: 0975.1005-019

U.S. Patent Application No. 10/187,121, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-020

U.S. Patent Application No. 10/186,559, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed June 28, 2002, Docket No.: 0975.1005-021

U.S. Patent Application No. 10/198,845, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 18, 2002, Docket No.: 0975.1005-022

U.S. Patent Application No. 10/200,795, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 22, 2002, Docket No.: 0975.1005-023

U.S. Patent Application No. 10/208,145, by Junming Le, Jan Vilcek, Peter Daddona, John Ghrayeb, David M. Knight and Scott Siegel, filed July 29, 2002, Docket No.: 0975.1005-024

Examiner

9/24/04
Date